Xenon Pharmaceuticals (XENE) announced that it has commenced an underwritten public offering of $500M of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair are acting as joint book-running managers for the proposed offering. Baird is acting as lead manager for the proposed offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals price target raised to $100 from $65 at Jefferies
- Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital
- Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
- Xenon Pharmaceuticals: Blockbuster Potential for Azetukalner After Outperforming Phase 3 Epilepsy Data Drives Target Hike to $80
- Xenon Pharmaceuticals: Azetuklaner’s Strong Phase III Data and Blockbuster Potential Underscore Undervalued Buy Opportunity